Unraveling potential neuroprotective mechanisms of herbal medicine for Alzheimer’s diseases through comprehensive molecular docking analyses

Unraveling potential neuroprotective mechanisms of herbal medicine for Alzheimer’s diseases through comprehensive molecular docking analyses

Alzheimer's disease (AD) continues to be a worldwide health concern, demanding innovative therapeutic approaches. This study investigates the neuroprotective potential of herbal compounds by scrutinizing their interactions with Beta-Secretase-1 (BACE1). Through comprehensive molecular docking a...

Full description

Bibliographic Details
Main Author:	Faisal Alsenani
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Series:	Saudi Journal of Biological Sciences
Subjects:	Alzheimer's disease Anthocyanins BACE1 Hederagenin Masticadienonic acid Molecular docking
Online Access:	http://www.sciencedirect.com/science/article/pii/S1319562X24000767

Similar Items

Identification of 3-Methoxycarpachromene and Masticadienonic Acid as New Target Inhibitors against Trypanothione Reductase from <i>Leishmania Infantum</i> Using Molecular Docking and ADMET Prediction
by: Sarra Maamri, et al.
Published: (2021-06-01)

The Potential Neuroprotective Effects of Extracts from Oat Seedlings against Alzheimer’s Disease
by: Won Seok Lee, et al.
Published: (2022-10-01)

Discovery of Sulforaphane as a Potent BACE1 Inhibitor Based on Kinetics and Computational Studies
by: Kumju Youn, et al.
Published: (2020-10-01)

Dual BACE1 and Cholinesterase Inhibitory Effects of Phlorotannins from <i>Ecklonia cava</i>—An In Vitro and in Silico Study
by: Jinhyuk Lee, et al.
Published: (2019-02-01)

Multitargeted Molecular Docking and Dynamic Simulation Studies of Bioactive Compounds from <i>Rosmarinus officinalis</i> against Alzheimer’s Disease
by: Fatima Javed Mirza, et al.
Published: (2022-10-01)

In vitro antiproliferative, anti-inflammatory effects and molecular docking studies of natural compounds isolated from Sarcocephalus pobeguinii (Hua ex Pobég)
by: Emmanuel Mfotie Njoya, et al.
Published: (2023-06-01)

AAV‐mediated delivery of an anti‐BACE1 VHH alleviates pathology in an Alzheimer's disease model
by: Marika Marino, et al.
Published: (2022-04-01)

Madecassic Acid—A New Scaffold for Highly Cytotoxic Agents
by: Oliver Kraft, et al.
Published: (2022-04-01)

Allostery Inhibition of BACE1 by Psychotic and Meroterpenoid Drugs in Alzheimer’s Disease Therapy
by: Samuel C. Ugbaja, et al.
Published: (2022-07-01)

A Diet Containing Rutin Ameliorates Brain Intracellular Redox Homeostasis in a Mouse Model of Alzheimer’s Disease
by: Paloma Bermejo-Bescós, et al.
Published: (2023-03-01)

Biological evaluation and interaction mechanism of beta-site APP cleaving enzyme 1 inhibitory pentapeptide from egg albumin
by: Zhipeng Yu, et al.
Published: (2020-06-01)

Identification of BACE-1 Inhibitors against Alzheimer’s Disease through E-Pharmacophore-Based Virtual Screening and Molecular Dynamics Simulation Studies: An Insilco Approach
by: Kumarappan Chidambaram
Published: (2023-04-01)

The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
by: Ulf Neumann, et al.
Published: (2018-11-01)

Proteomics identifies differentially expressed proteins in glioblastoma U87 cells treated with hederagenin
by: Yesen Zhang, et al.
Published: (2023-04-01)

Hederagenin Exerts Potential Antilipemic Effect via p38MAPK Pathway in Oleic Acid-induced HepG2 cells and in Hyperlipidemic Rats
by: MENG YANG, et al.
Published: (2022-09-01)

The role of PrPc in Alzheimer's disease related Amyloid-β hypothesis: a systematic review
by: Tomás Andrade Magalhães Gomes, et al.
Published: (2023-09-01)

Fangchinoline alleviates cognitive impairments through enhancing autophagy and mitigating oxidative stress in Alzheimer’s disease models
by: Lilin Yi, et al.
Published: (2023-12-01)

Computational screening for new neuroprotective ingredients against Alzheimer's disease from bilberry by cheminformatics approaches
by: Ran Xiao, et al.
Published: (2022-12-01)

Antioxidant and anti-Alzheimer activities of Clivia miniata (Lindl) roots, bulbs, and aerial parts: In-vitro and in-silico studies
by: Aya S. ElNagar, et al.
Published: (2023-11-01)

Microcurrent therapy as the nonpharmacological new protocol against Alzheimer’s disease
by: Eun Ho Kim, et al.
Published: (2024-01-01)

New Benzamides as Multi-Targeted Compounds: A Study on Synthesis, AChE and BACE1 Inhibitory Activity and Molecular Docking
by: Danuta Drozdowska, et al.
Published: (2023-10-01)

Insights into the mechanisms of non-coding RNAs’ implication in the pathogenesis of Alzheimer’s disease
by: Majid Khodayi-Shahrak, et al.
Published: (2022-06-01)

Synthesis, In Silico and In Vitro Evaluation for Acetylcholinesterase and BACE-1 Inhibitory Activity of Some <i>N</i>-Substituted-4-Phenothiazine-Chalcones
by: Thai-Son Tran, et al.
Published: (2020-08-01)

Scaffold Morphing and In Silico Design of Potential BACE-1 (β-Secretase) Inhibitors: A Hope for a Newer Dawn in Anti-Alzheimer Therapeutics
by: Shiveena Bhatia, et al.
Published: (2023-08-01)

Phytochemical Interactions with Calmodulin and Critical Calmodulin Binding Proteins Involved in Amyloidogenesis in Alzheimer’s Disease
by: Danton H. O'Day
Published: (2023-04-01)

Hydroxytyrosol–Donepezil Hybrids Play a Protective Role in an In Vitro Induced Alzheimer’s Disease Model and in Neuronal Differentiated Human SH-SY5Y Neuroblastoma Cells
by: Jessica Maiuolo, et al.
Published: (2023-08-01)

PTPRD and DCC Are Novel BACE1 Substrates Differentially Expressed in Alzheimer’s Disease: A Data Mining and Bioinformatics Study
by: Hannah A. Taylor, et al.
Published: (2022-04-01)

Glycosaminoglycans from <i>Litopenaeus vannamei</i> Inhibit the Alzheimer’s Disease β Secretase, BACE1
by: Courtney J. Mycroft-West, et al.
Published: (2021-04-01)

New Highly Selective BACE1 Inhibitors and Their Effects on Dendritic Spine Density In Vivo
by: Katrin Pratsch, et al.
Published: (2023-07-01)

Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology
by: Ferretti Maria, et al.
Published: (2012-04-01)

Bioassay-guided isolation of BACE1 inhibitors from Crataegus pinnatifida
by: Yajuan Zhou, et al.
Published: (2023-08-01)

Pharmacophore-Based Screening, Molecular Docking, and Dynamic Simulation of Fungal Metabolites as Inhibitors of Multi-Targets in Neurodegenerative Disorders
by: Danish Iqbal, et al.
Published: (2023-11-01)

Ajmalicine and Reserpine: Indole Alkaloids as Multi-Target Directed Ligands Towards Factors Implicated in Alzheimer’s Disease
by: Priya Kashyap, et al.
Published: (2020-04-01)

Circulating Small Extracellular Vesicle-Derived miR-342-5p Ameliorates Beta-Amyloid Formation via Targeting Beta-site APP Cleaving Enzyme 1 in Alzheimer’s Disease
by: Zhiwu Dong, et al.
Published: (2022-11-01)

BACE1 Inhibitors for Alzheimer’s Disease: The Past, Present and Any Future?
by: Firas H. Bazzari, et al.
Published: (2022-12-01)

Development of Activity Rules and Chemical Fragment Design for In Silico Discovery of AChE and BACE1 Dual Inhibitors against Alzheimer’s Disease
by: Le-Quang Bao, et al.
Published: (2023-04-01)

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study
by: Maarten Timmers, et al.
Published: (2018-08-01)

The Pursuit of the “Inside” of the Amyloid Hypothesis—Is C99 a Promising Therapeutic Target for Alzheimer’s Disease?
by: Nobumasa Takasugi, et al.
Published: (2023-01-01)

pHluorin-BACE1-mCherry Acts as a Reporter for the Intracellular Distribution of Active BACE1 In Vitro and In Vivo
by: Lu Zhao, et al.
Published: (2019-05-01)

Functional insights from targeted imaging BACE1: the first near-infrared fluorescent probe for Alzheimer’s disease diagnosis
by: Anyao Bi, et al.
Published: (2022-12-01)